CytomX Therapeutics Inc. (NASDAQ:CTMX) Director Ix L.P. Canaan sold 38,459 shares of CytomX Therapeutics stock in a transaction that occurred on Monday, November 28th. The shares were sold at an average price of $11.56, for a total transaction of $444,586.04. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Ix L.P. Canaan also recently made the following trade(s):

  • On Tuesday, November 22nd, Ix L.P. Canaan sold 42,550 shares of CytomX Therapeutics stock. The shares were sold at an average price of $11.71, for a total transaction of $498,260.50.
  • On Monday, November 21st, Ix L.P. Canaan sold 45,324 shares of CytomX Therapeutics stock. The shares were sold at an average price of $11.61, for a total transaction of $526,211.64.
  • On Wednesday, November 16th, Ix L.P. Canaan sold 51,581 shares of CytomX Therapeutics stock. The shares were sold at an average price of $11.50, for a total transaction of $593,181.50.
  • On Monday, November 14th, Ix L.P. Canaan sold 86,270 shares of CytomX Therapeutics stock. The shares were sold at an average price of $11.16, for a total transaction of $962,773.20.
  • On Wednesday, November 9th, Ix L.P. Canaan sold 13,730 shares of CytomX Therapeutics stock. The shares were sold at an average price of $11.03, for a total transaction of $151,441.90.

CytomX Therapeutics Inc. (NASDAQ:CTMX) opened at 11.28 on Tuesday. The firm’s 50-day moving average is $12.01 and its 200 day moving average is $11.69. The firm’s market capitalization is $410.61 million. CytomX Therapeutics Inc. has a 12 month low of $9.10 and a 12 month high of $24.68.

Insider Buying and Selling by Quarter for CytomX Therapeutics (NASDAQ:CTMX)

WARNING: This piece of content was originally reported by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are viewing this piece of content on another site, it was illegally stolen and republished in violation of US and international trademark and copyright legislation. The original version of this piece of content can be accessed at https://www.thecerbatgem.com/2016/11/29/cytomx-therapeutics-inc-ctmx-director-ix-l-p-canaan-sells-38459-shares.html.

Separately, Zacks Investment Research upgraded shares of CytomX Therapeutics from a “hold” rating to a “buy” rating and set a $12.00 price target for the company in a research report on Tuesday, November 8th.

Large investors have recently bought and sold shares of the stock. SG Americas Securities LLC purchased a new stake in CytomX Therapeutics during the third quarter valued at approximately $117,000. American International Group Inc. raised its stake in CytomX Therapeutics by 165.7% in the second quarter. American International Group Inc. now owns 11,759 shares of the company’s stock valued at $120,000 after buying an additional 7,333 shares during the period. Wells Fargo & Company MN raised its stake in CytomX Therapeutics by 253.6% in the third quarter. Wells Fargo & Company MN now owns 7,808 shares of the company’s stock valued at $122,000 after buying an additional 5,600 shares during the period. Nationwide Fund Advisors raised its stake in CytomX Therapeutics by 146.8% in the second quarter. Nationwide Fund Advisors now owns 12,925 shares of the company’s stock valued at $132,000 after buying an additional 7,688 shares during the period. Finally, BlackRock Inc. raised its stake in CytomX Therapeutics by 23.2% in the third quarter. BlackRock Inc. now owns 9,344 shares of the company’s stock valued at $146,000 after buying an additional 1,759 shares during the period. Hedge funds and other institutional investors own 54.19% of the company’s stock.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc is an oncology-focused biopharmaceutical company. The Company is engaged in the development of a class of antibody therapeutics based on its Probody technology platform. It uses its platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against a range of targets.

5 Day Chart for NASDAQ:CTMX

Receive News & Stock Ratings for CytomX Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics Inc. and related stocks with our FREE daily email newsletter.